Study Finds 33-Fold Rise in BPC-157 Use Despite Limited Safety Data
BPC-157, an unapproved peptide backed by RFK Jr. and often used with TB-500 as the “Wolverine stack,” is being consumed across a wide range of conditions in the gray market, with new-user numbers rising 33-fold from 2020 to 2026 and regulation still unresolved as the FDA weighs compounding despite safety concerns. Researchers warn that real-world use is hard to track, 1,039 documented patients exist, and there is no solid evidence that the peptide improves healing or pain, underscoring safety risks amid burgeoning popularity.
Health · 5 sources · Sep 16, 2026Read it
The journal
Open the journal →The conversation starts in the journal — be the first to post.
About BPC-157
Gastric pentadecapeptide BPC-157 is a synthetic fifteen amino acid oligopeptide derived from a protein found in human gastric juice. BPC-157 has been studied primarily in laboratory animals. BPC-157 is not approved by any drug regulatory agency for human use, and there is limited data regarding its effectiveness on humans.
Everything about BPC-157 →